Cargando…

Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas

Detalles Bibliográficos
Autores principales:	Mount, Christopher W., Majzner, Robbie G., Sundaresh, Shree, Arnold, Evan P., Kadapakkam, Meena, Haile, Samuel, Labanieh, Louai, Hulleman, Esther, Woo, Pamelyn J., Rietberg, Skyler P., Vogel, Hannes, Monje, Michelle, Mackall, Crystal L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214371/ https://www.ncbi.nlm.nih.gov/pubmed/29662203 http://dx.doi.org/10.1038/s41591-018-0006-x

Ejemplares similares

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
por: Monje, Michelle, et al.
Publicado: (2022)

Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling
por: Weber, Evan W., et al.
Publicado: (2021)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

IMMU-17. USE OF MRNA FOR SAFE AND EFFECTIVE GD2-DIRECTED CAR T CELLS TO TREAT DIFFUSE MIDLINE GLIOMAS
por: Foster, Jessica, et al.
Publicado: (2021)

c-Jun overexpression in CAR T cells induces exhaustion resistance
por: Lynn, Rachel C., et al.
Publicado: (2019)

Immune-Based Approaches for the Treatment of Pediatric Malignancies
por: Bosse, Kristopher R., et al.
Publicado: (2020)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
por: Mochizuki, Aaron, et al.
Publicado: (2021)

EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
por: Majzner, Robbie, et al.
Publicado: (2021)

Monosynaptic tracing maps brain-wide afferent oligodendrocyte precursor cell connectivity
por: Mount, Christopher W, et al.
Publicado: (2019)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

Inosine Induces Stemness Features in CAR T cells and Enhances Potency
por: Klysz, Dorota D., et al.
Publicado: (2023)

Anti-GD2 CAR T cells could prove transformative for H3-K27M(+) diffuse midline gliomas
por: Furukawa, Koichi, et al.
Publicado: (2019)

Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
por: Grosskopf, Abigail K., et al.
Publicado: (2022)

Erratum to anti-GD2 CAR T cells could prove transformative for H3-K27M(+) diffuse midline gliomas
por: Furukawa, Koichi, et al.
Publicado: (2019)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
por: Richards, Rebecca M., et al.
Publicado: (2021)

CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS
por: Barron, Tara, et al.
Publicado: (2023)

Floating Droplet Array: An Ultrahigh-Throughput Device for Droplet Trapping, Real-time Analysis and Recovery
por: Labanieh, Louai, et al.
Publicado: (2015)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

GD2 CAR T cells against human glioblastoma
por: Prapa, Malvina, et al.
Publicado: (2021)

Rapid Detection of β-Lactamase-Producing Bacteria Using the Integrated Comprehensive Droplet Digital Detection (IC 3D) System
por: Li, Yiyan, et al.
Publicado: (2020)

IMMU-11. LOCOREGIONAL DELIVERY OF TRANSIENT GD2 CAR T CELLS FOR SAFE AND EFFECTIVE TREATMENT OF DIPG
por: Foster, Jessica, et al.
Publicado: (2020)

HGG-04. TARGETING GABAERGIC NEURON-GLIOMA SYNAPSES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THROUGH ANTI-EPILEPTIC DRUG REPURPOSING
por: Barron, Tara, et al.
Publicado: (2021)

Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model
por: Murty, Surya, et al.
Publicado: (2020)

Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma
por: Golinelli, Giulia, et al.
Publicado: (2021)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

HGG-05. NEURONAL ACTIVITY PROMOTES PEDIATRIC HIGH-GRADE GLIOMA GROWTH THROUGH A NLGN3-CSPG4 SIGNALING AXIS
por: Gillespie, Shawn, et al.
Publicado: (2021)

In vivo imaging of nanoparticle-labeled CAR T cells
por: Kiru, Louise, et al.
Publicado: (2022)

Aptamer technology for tracking cells’ status & function
por: Wiraja, Christian, et al.
Publicado: (2014)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas
por: Wei, Xin, et al.
Publicado: (2021)

Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice
por: Thomas, Ancy, et al.
Publicado: (2021)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant
por: de Billy, Emmanuel, et al.
Publicado: (2021)

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
por: Mahdi, Jasia, et al.
Publicado: (2023)

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
por: Mabe, Nathaniel W., et al.
Publicado: (2022)

Immunotherapy of Neuroblastoma: Facts and Hopes
por: Anderson, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2dtg5c14t3cjl90u63aentc7ff